thalidomide has been researched along with Fever in 15 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 7.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 6.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 5.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 3.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 2.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| "Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL)." | 2.78 | Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. ( Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG, 2013) |
| "Environmental causes of birth defects have increasingly been recognized since the mid-20th century." | 2.47 | Causes of birth defects: lessons from history. ( Lancaster, PA, 2011) |
| "Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month." | 1.91 | Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). ( Deng, M; Han, T; Li, Y; Mao, H; Mo, W, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banday, AZ | 1 |
| Joshi, V | 1 |
| Arora, K | 1 |
| Sadanand, R | 1 |
| Basu, S | 1 |
| Pilania, RK | 1 |
| Jindal, AK | 1 |
| Vignesh, P | 1 |
| Gupta, A | 1 |
| Sharma, S | 1 |
| Dhaliwal, M | 1 |
| Rawat, A | 1 |
| Singh, S | 1 |
| Suri, D | 1 |
| Li, Y | 1 |
| Deng, M | 1 |
| Han, T | 1 |
| Mo, W | 1 |
| Mao, H | 1 |
| Soriano, A | 1 |
| Soriano, M | 1 |
| Espinosa, G | 1 |
| Manna, R | 1 |
| Emmi, G | 1 |
| Cantarini, L | 1 |
| Hernández-Rodríguez, J | 1 |
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 1 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 1 |
| Damaj, G | 1 |
| Geng, C | 1 |
| Hou, J | 1 |
| Zhao, Y | 1 |
| Ke, X | 1 |
| Wang, Z | 1 |
| Qiu, L | 1 |
| Xi, H | 1 |
| Wang, F | 1 |
| Wei, N | 1 |
| Liu, Y | 1 |
| Yang, S | 1 |
| Wei, P | 1 |
| Zheng, X | 1 |
| Huang, Z | 1 |
| Zhu, B | 1 |
| Chen, WM | 1 |
| Lai, YT | 1 |
| Tsai, YP | 1 |
| Cherng, CG | 1 |
| Ke, JJ | 1 |
| Ho, MC | 1 |
| Tsai, CW | 1 |
| Yu, L | 1 |
| Lancaster, PA | 1 |
| Morita, Y | 1 |
| Shimada, T | 1 |
| Yamaguchi, T | 1 |
| Rai, S | 1 |
| Hirase, C | 1 |
| Emoto, M | 1 |
| Serizawa, K | 1 |
| Taniguchi, Y | 1 |
| Ojima, M | 1 |
| Tatsumi, Y | 1 |
| Ashida, T | 1 |
| Matsumura, I | 1 |
| Badoux, XC | 1 |
| Keating, MJ | 1 |
| Wen, S | 1 |
| Wierda, WG | 1 |
| O'Brien, SM | 1 |
| Faderl, S | 1 |
| Sargent, R | 1 |
| Burger, JA | 1 |
| Ferrajoli, A | 1 |
| Marque, M | 1 |
| Guillot, B | 1 |
| Bessis, D | 1 |
| Thornburg, A | 1 |
| Abonour, R | 1 |
| Smith, P | 1 |
| Knox, K | 1 |
| Twigg, HL | 1 |
| Haslett, P | 1 |
| Tramontana, J | 1 |
| Burroughs, M | 1 |
| Hempstead, M | 1 |
| Kaplan, G | 1 |
| Deaner, P | 1 |
| Drenth, JP | 1 |
| Vonk, AG | 1 |
| Simon, A | 1 |
| Powell, R | 1 |
| van der Meer, JW | 1 |
| DeFeo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292[NCT00759603] | Phase 2 | 60 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly & constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes>1500/µL, platelets>100,000/µL, hemoglobin>11.0 g/dL (untransfused); lymphocyte count <5,000/µL; Bone marrow aspirate & biopsy normocellular for age with <30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia & bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets>100,000/µL or 50% improvement; Hemoglobin>11.0 g/dL (untransfused) or 50% improvement. (NCT00759603)
Timeframe: Responses assessed after 12 cycles, up to 48 weeks with interim assessments performed after 3, 6 and 12 cycles.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Lenalidomide + Rituximab | 66 |
3 reviews available for thalidomide and Fever
| Article | Year |
|---|---|
Challenges in the diagnosis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome in developing countries-A decade of experience from North India.
Topics: Antipyretics; Antiviral Agents; Child; Colchicine; Developing Countries; Fever; Humans; Lymphadeniti | 2022 |
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve | 2020 |
Causes of birth defects: lessons from history.
Topics: Abnormalities, Drug-Induced; Animals; Australia; Congenital Abnormalities; Female; Fever; History, 2 | 2011 |
4 trials available for thalidomide and Fever
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2014 |
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Acute-Phase Reaction; Adult; Cross-Over Studies; Cytokines; DNA Mutational Analysis; Double-Blind Me | 2001 |
8 other studies available for thalidomide and Fever
| Article | Year |
|---|---|
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).
Topics: Adalimumab; Anemia, Sideroblastic; Female; Fever; Humans; Immunoglobulins, Intravenous; Immunologic | 2023 |
Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inh | 2009 |
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Mult | 2011 |
Thalidomide for treatment of PFAPA syndrome.
Topics: Adult; Fever; Humans; Immunosuppressive Agents; Lymphadenitis; Male; Periodicity; Pharyngitis; Recur | 2007 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dys | 2007 |
Adverse reactions to thalidomide in patients infected with human immunodeficiency virus.
Topics: Adult; CD4 Lymphocyte Count; Female; Fever; HIV Infections; Humans; Male; Prospective Studies; Skin; | 1997 |
Thalidomide for distressing night sweats in advanced malignant disease.
Topics: Fever; Humans; Hyperhidrosis; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Thalidomide | 1998 |
Hansenosis of the neurotrophic type.
Topics: Adult; Fever; Humans; Leprosy; Male; Nervous System Diseases; Skin; Sulfones; Thalidomide | 1969 |